Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy

Antiviral Therapy

Volumn 17, Issue 6, 2012, Pages 1049-1058

  Van Bömmel, Florian ^a   Trojan, Jörg ^b   Deterding, Katja ^c   Wedemeyer, Heiner ^c   Wasmuth, Hermann E ^d   Hüppe, Dietrich ^e   Möller, Bernd ^f   Bock, Friederike J ^g   Feucht, Heinz Hubert ^h   Berg, Thomas ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Gastroenterol Schwerpunktpraxis   (Germany)

^f Hepatologische Schwerpunktpraxis   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Laborgemeinschaft Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLONAL VARIATION; CROSS RESISTANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR EVOLUTION; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STRUCTURAL GENE; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS GENE; VIRUS MUTATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; CLONING, MOLECULAR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; ESCHERICHIA COLI; EVOLUTION, MOLECULAR; FEMALE; FOLLOW-UP STUDIES; GENE PRODUCTS, POL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; VIREMIA;

EID: 84865728581     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2307     Document Type: Article

References (27)

1. Wiegand J, van Bömmel F, Berg T. Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis 2010; 30:361-377.
2. Heathcote E, Gane EJ, De Man RA, et al. Long-term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103). Hepatology 2010; 52:145A.
3. Marcellin P, Buti M, Krastev Z, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatits B (study 102). Hepatology 2010; 52:145A.
4. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53:763-773.
5. van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44:318-325.
6. Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48:391-398.
7. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139:1207-1217.
8. Levrero M, Cimino L, Lampertico P, et al. Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment: results of the OptiB Italian multicenter prospective open label study. Hepatology 2010; 52:96A.
9. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751.
12. Lada O, Benhamou Y, Cahour A, et al. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9:353-363.
13. Delaney WE, IV, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471-2477.
14. Qi X, Xiong S, Yang H, et al. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12:355-362.
15. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-1398.
16. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60:247-254.
17. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51:73-80.
18. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
19. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
20. Zöllner B, Petersen J, Puchhammer-Stöckl E, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39:42-50.
21. Stuyver L, Van Geyt C, De Gendt S, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000; 38:702-707.
22. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
23. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254-265.
24. Karatayli E, Karayalçin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007; 12:761-768.
25. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734.
26. Reijnders JG, Pas SD, Schutten M, et al. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009; 50:674-683.
27. Lai CL, Elion R, Sherman M, et al. Entecavir (ETV) therapy in chronic hepatitis B patients previously treated with adefovir (ADV) with incomplete response on-treatment or relapse off-treatment. J Hepatol 2009; 50:S334.